NEW CFO AND NEW GENERAL COUNSEL
VANCOUVER, BRITISH COLUMBIA – January 11, 2021 - Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the Company’s appointment of Stephen R. Brooks as its new Chief Financial Officer and Peter Rizakos as the firm’s new General Counsel.
EARLY DIAGNOSIS AND TREATMENT
VANCOUVER, BRITISH COLUMBIA – January 8, 2021 - Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announces the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article – Bipolar Disorders – is published in one of the world’s best-known and most reputable scientific journals in medicine - The Lancet.
MATERIAL CHANGE REPORT - DEC 10, 2020
Material Change Report - December 10, 2020
Material Change Report
Material Change Report - December 10, 2020
INTERIM CHIEF FINANCIAL OFFICER
VANCOUVER, BRITISH COLUMBIA (December 8, 2020) – Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), today announced that Christopher Hobbs will join the Company as Interim Chief Financial Officer (CFO), effective December 8, 2020. Stephen Brohman, the Company’s current contract CFO, has resigned from the position, effective December 7, 2020.
CHANGES AT THE TOP
VANCOUVER, BRITISH COLUMBIA (November 24, 2020) - Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced today that the Company’s management and governance is undergoing comprehensive change at the top that will extend to the Company’s practices.
OPENS SECOND LOCATION
Mississauga, Ontario – Monday, November 9, 2020 – The Canadian Rapid Treatment Center of Excellence (the “CRTCE”) announces today the opening of a new clinic in downtown Toronto. Both the existing Mississauga clinic and newly opened Toronto clinic (the “CRTCE Clinics”) address the unmet need of depression and suicide through novel ketamine therapy treatment.
UPDATE ON CONTINUOUS DISCLOSURE REVIEW
VANCOUVER, BRITISH COLUMBIA (October 29, 2020) – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) continues to work diligently with the British Columbia Securities Commission (the “Commission”) to address the ongoing continuous disclosure review and to coordinate the revocation of the existing cease trade order.
DR. ROGER MCINTYRE ELECTED BOARD CHAIR
VANCOUVER, BRITISH COLUMBIA (October 5, 2020) - Dr. Roger McIntyre has been elected Chairman of the Board of Directors of Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF).
UPDATE ON DISCLOSURE REVIEW
VANCOUVER, British Columbia, September 15, 2020 – Champignon Brands Inc. (CSE: SHRM) (the “Company”) continues to work with the British Columbia Securities Commission (the “Commission”) to address an ongoing continuous disclosure review.
CHAMPIGNON TO BEGIN OFFERING ESKETAMINE
VANCOUVER, British Columbia, August 27, 2020 – Champignon Brands Inc. (CSE: SHRM) (the “Company” or “Champignon”) is expanding its rapid-onset treatment service for major depressive disorder (“MDD”).
CHAMPIGNON ANNOUNCES FILING OF BUSINESS ACQUISITION
VANCOUVER, British Columbia, July 24, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) is pleased to announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. Copies of the reports are available for review under the Company’s profile on SEDAR